^
    2d
    Computational validation of inhibitors for human phosphatidylinositol 4-phosphate 5-kinase-type 1 α protein implicated in cancer. (PubMed, J Biomol Struct Dyn)
    Four protein kinase inhibitors, R547, GDC-0879, JNJ-7706621 and ABT-869 were found to bind hPIP5K1α via a stable complex formation. The hit molecules display favorable ADME properties and are predicted to be non-carcinogenic. The hit molecules in particular R547, have better binding free energies compared to reference molecule, ISA-2011B.
    Journal
    |
    PIP5K1A (Phosphatidylinositol-4-Phosphate 5-Kinase Type 1 Alpha)
    |
    GDC 0879 • linifanib (ABT-869) • R-547
    4d
    CDX0159-16: Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism (2025-522583-32-00)
    P2/3, N=126, Not yet recruiting, Celldex Therapeutics Inc.
    New P2/3 trial
    8d
    CDX0159-16: Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism (2025-522583-32-00)
    P2/3, N=80, Not yet recruiting, Celldex Therapeutics Inc.
    New P2/3 trial
    15d
    CDX0159-17: Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria (2025-522878-36-00)
    P2/3, N=253, Not yet recruiting, Celldex Therapeutics Inc.
    New P2/3 trial
    17d
    Benign Keratoses With Inverted Follicular Keratosis-Like Features in a Patient Receiving Ripretinib: A Case Report. (PubMed, J Cutan Pathol)
    Inverted follicular keratosis (IFK) is a rare benign neoplasm of the follicular infundibulum and typically presents as a solitary, nonpigmented verrucous papule on the head and neck of older males and can mimic viral warts, basal cell carcinoma (BCC), or squamous cell carcinoma (SCC). To the best of our knowledge, this represents the first reported association between repretinib treatment and benign keratoses with IFK-like features. Further studies are needed to clarify the clinical significance and biological implications of this observation.
    Journal
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    Qinlock (ripretinib)
    22d
    Ultrasound-triggered dissolving microneedle platform for cGAS-STING-mediated precision immunotherapy of melanoma. (PubMed, Mater Today Bio)
    Herein, we reported an ultrasound (US)-controllable all-in-one dissolving microneedle (dMN) platform that integrated a ROS-cleavable prodrug, formed by conjugating the VEGF inhibitor linifanib, with ROS-responsive liposomes encapsulating the sonosensitizer MnTCPP (Mn@CTL-LPs dMNs)...This spatiotemporally controllable activation ensured high therapeutic precision and safety. Overall, this work presented a noninvasive and US-triggered strategy to potentiate sonodynamic immunotherapy for melanoma.
    Journal
    |
    CD8 (cluster of differentiation 8) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    linifanib (ABT-869)
    1m
    EGFR/KIT-linked proliferative bias in normal breast lobules from matched non-Hispanic Black and White women is rapidly reversible by RTK inhibition. (PubMed, Am J Pathol)
    Functional plausibility was assessed in pre-stasis human mammary epithelial cells (HMECs) exposed for 24 h to clinically relevant EGFR (lapatinib) or KIT (ripretinib) inhibitors. Together, matched normal tissue and primary-cell data indicate a coordinated EGFR/KIT-linked proliferative bias in NHBW epithelium that is rapidly reversible in vitro. These findings motivate composition-aware validation in larger normal-tissue cohorts and pharmacodynamic window studies to test whether short-term RTK modulation can reset proliferation-biased states in at-risk breast epithelium.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    lapatinib • Qinlock (ripretinib)
    1m
    EMBARQ-CSU1: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (clinicaltrials.gov)
    P3, N=963, Active, not recruiting, Celldex Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    1m
    EMBARQ-CSU2: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) (clinicaltrials.gov)
    P3, N=976, Active, not recruiting, Celldex Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    1m
    A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, Jasper Therapeutics, Inc. | Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2026 --> Aug 2026
    Enrollment closed • Trial primary completion date
    |
    briquilimab (JSP191)
    1m
    BLU-808-1201: Study of BLU-808 in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria (2024-520031-33-00)
    P1/2, N=57, Recruiting, Blueprint Medicines Corp.
    New P1/2 trial
    1m
    CHILL-MC: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Tolerability, Pharmacokinetic, Pharmacodynamic, and Preliminary Efficacy Trial of GTX-B001 in Healthy Volunteers (Part A) and Patients with Chronic Inducible Urticaria (Part B) (2025-522126-13-00)
    P1, N=56, Recruiting, Granular Therapeutics Limited
    New P1 trial